Impact of switching from human immunodeficiency virus type 1 protease inhibitors to Efavirenz in successfully treated adults with lipodystrophy

Clinical Infectious Diseases

Volumn 31, Issue 5, 2000, Pages 1266-1273

  Martinez, Esteban ^a   García Viejo, Miguel Angel ^a   Blanco, Josຉ Luis ^a   Bianchi, Luis ^a   Buira, Elisabet ^a   Conget, Ignacio ^a   Casamitjana, Roser ^a   Mallolas, Josep ^a   Gatell, José M ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; EFAVIRENZ; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL; VIRUS RNA;

ADULT; ANTHROPOMETRY; ARTICLE; BODY COMPOSITION; BODY FAT; BODY MASS; CLINICAL ARTICLE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPODYSTROPHY; LYMPHOCYTE COUNT; MALE; NONHUMAN; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS LOAD;

ADIPOSE TISSUE; ADULT; BLOOD GLUCOSE; BODY CONSTITUTION; BODY MASS INDEX; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LIPIDS; LIPODYSTROPHY; MALE; MIDDLE AGED; OXAZINES; PROTEASE INHIBITORS; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0034456220     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/317426     Document Type: Article

References (35)

1. Indinavir-associated lipodystrophy
2. "Buffalo hump" in men with HIV-1 infection
3. Visceral abdominal-fat accumulation associated with use of indinavir
4. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
5. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study
6. Cumulative risk for developing protease inhibitor-associated lipodystrophy
7. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy
8. Lipodystrophy in patients naive to HIV protease inhibitors
9. Reversion of lipodystrophy after switching from HIV-1 protease inhibitors to nevirapine
10. Reversibility of protease inhibitor lipodystrophy syndrome on stopping protease inhibitors or switching to nelfinavir
11. A multi-center, randomized, open-label, comparative trial of the clinical benefit of switching the protease inhibitor by nevirapine in HAART-experienced patients suffering lipodystrophy
12. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
13. Lack of clinical lipodystrophy in patients receiving efavirenz plus NRTIs in Study 006
14. Potential adverse experiences associated with efavirenz in adults
15. Management of protease inhibitor-associated lipodystrophy by substitution with efavirenz in virologically controlled HIV-infected persons
16. Prospective follow-up of a protease inhibitor substitution for efavirenz in patients with HIV-related lipodystrophy syndrome
17. Replacing a protease inhibitor with efavirenz for management of protease inhibitor toxicity
18. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
19. Detection and evaluation of dyslipoproteinemia
20. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus
21. A simple measure of insulin resistance
22. Detection of low HIV-1 RNA levels in plasma
23. Increasing prevalence of overweight among U.S. adults: The national health and nutrition examination surveys, 1960-1991
24. Selection of anthropometric indicators for classification of abdominal famess - A critical review
25. A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution
26. Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy
27. Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV
28. The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy
29. Switch to AZT plus 3TC improves lipodystrophy in the presence of protease inhibitors
30. Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy
31. Fat distribution in HIV-infected patients reporting truncal enlargement quantified by whole-body magnetic resonance imaging
32. Heterogeneity in adipose tissue metabolism: Causes, implications and management of regional adiposity
33. Sonography detection of small intra-abdominal fat variations
34. Efavirenz as a substitute for protease inhibitors in HIV-infected patients on triple-drug therapy with plasma viral load below 20 copies/mL
35. Switch from protease inhibitors to once daily non-nucleoside reverse transcriptase inhibitors in HIV-infected patients maintaining undetectable plasma viral loads on protease inhibitor-containing regimens: The Maintavir Study